LUND, Sweden—- Phase II data presented in May shows that the antithrombotic effect of TB-402 is better than enoxaparin, the current standard treatment. In May BioInvent and ThromboGenics achieved a milestone corresponding to EUR 10 million when development partner Roche launched a new clinical study with the product candidate TB-403.
